Aapro 2008.

Methods	randomized controlled trial, not placebo‐controlled
Participants	n = 463, breast cancer (M1); concomitant treatment: chemotherapy
Interventions	drug = Epoetin beta dose = 30000 IU sc weekly hb‐target = 13‐15 d/dL planned ESA duration = 24 weeks
Outcomes	Primary: overall survival; secondary: progression free survival, tumor response rate, QoL
Notes	study number = 97413
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	no description
Allocation concealment?	Low risk	central randomization